HOME

Malta

Our Presence

Malta

Secretary/General Information

Our Presence

Medis GmbH
campus 21, Europaring F15/301
A-2345 Brunn am Gebirge

Secretary/General Information

Medis GmbH
campus 21, Europaring F15/301
A-2345 Brunn am Gebirge

Secretary/General Information
 

Medis GmbH
campus 21, Europaring F15/301
A-2345 Brunn am Gebirge

Secretary/General Information
 

In Malta, the reimbursement of rare disease treatments is managed by the national health authority, the Malta Medicines Authority (MMA). The MMA is responsible for assessing and approving the reimbursement of drugs and other medical products, including those used to treat rare diseases.

The process for reimbursement of rare disease treatments in Malta involves an application from the pharmaceutical company, which is reviewed by the MMA’s pricing and reimbursement committee. The committee evaluates the clinical and cost-effectiveness of the product, as well as the impact on the national health budget. The committee also considers the availability of alternative treatments and the level of unmet medical need for the specific rare disease.

Once the committee has reviewed the application, they make a recommendation to the MMA’s board, which makes the final decision on reimbursement. If the product is approved for reimbursement, it will be added to the Malta National Formulary, which is the list of reimbursed drugs and medical products available to patients.

It is important to note that the reimbursement process for rare disease treatments can be complex and challenging, as the patient population is often small and the cost of treatment may be high. However, the MMA is committed to ensuring that patients with rare diseases have access to the treatments they need, and they work closely with pharmaceutical companies and patient advocacy groups to facilitate the reimbursement process.